Vaxcyte, Inc. 4

Vaxcyte CMO Luis Jodar was granted 52,632 RSUs and options for 88,254 shares of common stock at $61.16 per share as part of equity compensation on 2026-09-04.

On September 4, 2026, Vaxcyte, Inc. Chief Medical Officer Luis Jodar received an equity compensation package consisting of 52,632 restricted stock units (each RSU representing one share of common stock) and a stock option grant for 88,254 shares at an exercise price of $61.16 per share. The RSUs vest as to one quarter of the award on September 7, 2027 and one eighth every six months thereafter, contingent on continued service, while the stock options vest 25% on August 31, 2027 with the remaining 75% vesting in equal monthly installments over the subsequent three years, also subject to continued service. These are new awards rather than open-market purchases or sales and are typical of senior executive compensation, increasing Jodar’s derivative and underlying common stock exposure to Vaxcyte over a long-dated vesting horizon.

Filing Facts

CIK

1649094

Ticker

PCVX

Form

4

Source Type

fda

Accession

0002151661-26-000004

Alert Tier

5